TMHC trades 1.6% below Wall Street's consensus target of $72.75.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TMHC achieves its forward estimates and maintains a stable P/E multiple of 13.5x. This scenario reflects the blended consensus of 31 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Taylor Morrison Home Corporation (TMHC) has a Wall Street consensus price target of $72.75, based on estimates from 31 covering analysts. With the stock currently trading at $71.58, this represents a potential upside of +1.6%. The company has a market capitalization of $6.69B.
Analyst price targets range from a low of $70.00 to a high of $76.00, representing a 8% spread in expectations. The median target of $72.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TMHC trades at a trailing P/E of 9.2x and forward P/E of 13.5x. The forward PEG ratio of 0.41 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -23.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $81.90, with bear and bull scenarios of $51.59 and $107.91 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
DHID.R. Horton, Inc. | $45.7B | $157.81 | $163.86 | +3.8% | Hold | 14.9x | 52 |
LENLennar Corporation | $22.3B | $89.73 | $89.17 | -0.6% | Buy | 15.8x | 50 |
PHMPulteGroup, Inc. | $24.4B | $126.96 | $144.50 | +13.8% | Hold | 12.7x | 44 |
TOLToll Brothers, Inc. | $14.7B | $155.67 | $173.88 | +11.7% | Hold | 12.2x | 46 |
NVRNVR, Inc. | $18.0B | $6490.93 | $7465.33 | +15.0% | Buy | 18.0x | 24 |
MHOM/I Homes, Inc. | $3.8B | $149.09 | $165.00 | +10.7% | Hold | 11.3x | 10 |
KBHKB Home | $3.4B | $54.20 | $60.43 | +11.5% | Hold | 16.9x | 43 |
TPHTri Pointe Homes, Inc. | $4.0B | $46.96 | $47.00 | +0.1% | Hold | 24.5x | 22 |
CVCOCavco Industries, Inc. | $4.6B | $601.51 | $700.00 | +16.4% | Buy | 25.2x | 2 |
SKYChampion Homes, Inc. | $4.6B | $83.34 | $93.00 | +11.6% | Buy | 22.1x | 8 |
Quick answers to the most common questions about buying TMHC stock.
The consensus price target for TMHC is $72.75, close to the current price of $71.58 (1.6% implied move). Based on 31 analyst estimates, the stock appears fairly valued near current levels.
TMHC has a consensus rating of "Buy" based on 31 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $72.75 implies 1.6% upside from current levels.
With a forward P/E of 13.5057x, TMHC trades at a relatively low valuation. The consensus target of $72.75 implies 1.6% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $76 for TMHC, while the most conservative target is $70. The consensus of $72.75 represents the median expectation. Our quantitative valuation model projects a bull case target of $108 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TMHC is heavily covered by Wall Street, with 31 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 14 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TMHC stock forecast based on 31 Wall Street analysts shows a consensus price target of $72.75, with estimates ranging from $70 (bear case) to $76 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $82, with bear/bull scenarios of $52/$108.
Our quantitative valuation model calculates TMHC's fair value at $82 (base case), with a bear case of $52 and bull case of $108. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
TMHC trades at a forward P/E ratio of 13.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 9.2x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
TMHC appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $72.75 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TMHC analyst price targets range from $70 to $76, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $72.75 consensus represents the middle ground. Our model's $52-$108 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.